These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 19647813

  • 1. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.
    J Eval Clin Pract; 2011 Dec 05; 17(6):1050-8. PubMed ID: 21679279
    [Abstract] [Full Text] [Related]

  • 4. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Dec 05; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 5. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 6. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J.
    Vaccine; 2007 Sep 17; 25(37-38):6677-91. PubMed ID: 17706844
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug 17; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

  • 8. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 9. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.
    Vaccine; 2009 Oct 19; 27(44):6196-202. PubMed ID: 19698807
    [Abstract] [Full Text] [Related]

  • 10. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis.
    Rogoza RM, Ferko N, Bentley J, Meijer CJ, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL.
    Vaccine; 2008 Sep 15; 26 Suppl 5():F46-58. PubMed ID: 18992382
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Sep 15; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 12. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL.
    Sex Health; 2010 Sep 15; 7(3):376-82. PubMed ID: 20719230
    [Abstract] [Full Text] [Related]

  • 13. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 14. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.
    BJOG; 2012 Jan 19; 119(2):177-86. PubMed ID: 21794070
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier Bosch F, de Sanjosé S, Franco EL.
    Vaccine; 2007 Aug 14; 25(33):6257-70. PubMed ID: 17606315
    [Abstract] [Full Text] [Related]

  • 16. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL, Coutlée F, Ferenczy A.
    Public Health Genomics; 2009 Aug 14; 12(5-6):352-61. PubMed ID: 19684447
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [Abstract] [Full Text] [Related]

  • 18. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY.
    Vaccine; 2008 Aug 19; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [Abstract] [Full Text] [Related]

  • 19. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G, Howard K, Webster A, Chapman JR, Craig JC.
    Transplantation; 2009 Apr 15; 87(7):1078-91. PubMed ID: 19352131
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.
    Vaccine; 2009 Jul 30; 27(35):4776-83. PubMed ID: 19539578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.